Germany’s Merck KGaA (MRK: DE) has announced a licensing agreement with New York-based small molecule developer Inspirna.
The deal relates to a first-in-class SLC6A8 blocker, ompenaclid, and will include other similar follow-on compounds.
Ompenaclid is currently being evaluated in a Phase II trial for the second-line treatment of certain people with advanced or metastatic colorectal cancer (mCRC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze